Ownership Change to Note: Fate Therapeutics Inc (NASDAQ:FATE) Sentiment Falls in 2016 Q2

November 17, 2016 - By Clifton Ray   ·   0 Comments

Ownership Change to Note: Fate Therapeutics Inc (NASDAQ:FATE) Sentiment  Falls in  2016 Q2

Sentiment for Fate Therapeutics Inc (NASDAQ:FATE)

Fate Therapeutics Inc (NASDAQ:FATE) institutional sentiment decreased to 0.56 in Q2 2016. Its down -0.40, from 0.96 in 2016Q1. The ratio dived, as 10 investment professionals opened new and increased holdings, while 18 decreased and sold stakes in Fate Therapeutics Inc. The investment professionals in our partner’s database now own: 13.89 million shares, down from 15.66 million shares in 2016Q1. Also, the number of investment professionals holding Fate Therapeutics Inc in their top 10 holdings was flat from 2 to 2 for the same number . Sold All: 7 Reduced: 11 Increased: 9 New Position: 1.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $90.93 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

About 42,194 shares traded hands. Fate Therapeutics Inc (NASDAQ:FATE) has risen 30.73% since April 15, 2016 and is uptrending. It has outperformed by 26.11% the S&P500.

According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”

Polaris Venture Management Co. V L.L.C. holds 4.51% of its portfolio in Fate Therapeutics Inc for 2.47 million shares. Belmont Global Advisors Inc. owns 400,000 shares or 0.65% of their US portfolio. Moreover, Redmile Group Llc has 0.24% invested in the company for 1.50 million shares. The New York-based Kingdon Capital Management L.L.C. has invested 0.21% in the stock. Board Of Trustees Of The Leland Stanford Junior University, a California-based fund reported 291,067 shares.#img1#

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Ratings analysis reveals 100% of Fate Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Fate Therapeutics, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4 while the high is $8. The stock’s average target of $6.75 is 163.67% above today’s ($2.56) share price. FATE was included in 6 notes of analysts from October 6, 2015. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The rating was initiated by TH Capital on Thursday, September 22 with “Buy”. Raymond James initiated Fate Therapeutics Inc (NASDAQ:FATE) on Tuesday, October 6 with “Outperform” rating. The rating was maintained by Wedbush with “Outperform” on Tuesday, November 8. The rating was initiated by Roth Capital on Thursday, September 22 with “Buy”. BMO Capital Markets initiated Fate Therapeutics Inc (NASDAQ:FATE) on Tuesday, April 12 with “Outperform” rating.

FATE Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

More news for Fate Therapeutics Inc (NASDAQ:FATE) were recently published by: 247Wallst.com, which released: “Could This Be a Turning Point for Fate Therapeutics?” on June 20, 2016. Globenewswire.com‘s article titled: “Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch …” and published on September 07, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>